Immunomodulation and entry inhibition: selgantolimod's double punch against hepatitis B virus

Gut. 2024 Nov 11;73(12):1925-1926. doi: 10.1136/gutjnl-2024-332679.

Thomas Baumert^{1

2

3}, Melanie Urbanek-Quaing^{4

5}, Markus Cornberg^{6

5}

¹ Inserm UMR_S1110, University of Strasbourg, Strasbourg, France.
² Hepatology-Gastroenterology Service, Strasbourg University Hospitals, Strasbourg, France.
³ Institute for Translational Medicine and Liver Disease, University of Strasbourg, Strasbourg, France.
⁴ Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
⁵ Centre for Individualised Infection Medicine (CiiM), Hannover, Germany.
⁶ Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany [email protected].

No abstract available

Keywords: ANTIVIRAL THERAPY; CYTOKINES; HEPATITIS B; KUPFFER CELL.

Grants and funding